C3AR1 Antibody

What is C3AR1 and why is it important for immunological research?

C3AR1 (complement component 3a receptor 1) is a 482 amino acid protein (53.9 kDa) with membrane subcellular localization that belongs to the G-protein coupled receptor 1 family. It functions in complement receptor activity and complement component C3a receptor activity, playing significant roles in signal transduction, innate immune system function, and GPCR signaling. The receptor is particularly important in immunological research because it mediates immune cell activation and migration in response to complement activation products, specifically C3a . Its tissue-specific expression has been observed in brain, heart, lung, placenta, spleen, and intestine, making it relevant for studying immune responses across multiple organ systems .

How do I select the appropriate C3AR1 antibody for my specific research application?

When selecting a C3AR1 antibody, consider these methodological factors:

• Application compatibility: Determine whether the antibody has been validated for your specific application (Western blot, flow cytometry, IHC, IF or ELISA)

• Species reactivity: Verify that the antibody recognizes C3AR1 in your experimental species (human, mouse, rat, etc.)

• Clonality considerations:

  • Monoclonal antibodies: Offer higher specificity for a single epitope and batch-to-batch consistency

  • Polyclonal antibodies: Recognize multiple epitopes, potentially providing stronger signals but with more batch variation

• Epitope location: For membrane proteins like C3AR1, antibodies targeting extracellular domains are preferred for flow cytometry and live-cell applications, while those targeting intracellular domains may work better for fixed-cell applications

• Validation data: Review published literature and supplier validation data showing the antibody's performance in contexts similar to your experimental design

What are the key differences between detecting C3AR1 in human versus mouse models?

The human C3AR1 protein shares approximately 65% sequence homology with its mouse ortholog, resulting in important experimental considerations:

• Antibody cross-reactivity: Most C3AR1 antibodies are species-specific and won't cross-react; verify species reactivity in product documentation

• Expression pattern differences: While both human and mouse C3AR1 are expressed in myeloid cells, expression levels and patterns may differ between species in certain tissues and states

• Receptor glycosylation variations: Post-translational modifications, particularly glycosylation patterns, differ between species affecting antibody recognition and apparent molecular weight in Western blots

• Experimental validation: When translating findings between species, use species-appropriate positive controls to confirm antibody specificity

• Knockout controls: For mouse studies, C3ar1-/- tissues provide ideal negative controls to validate antibody specificity

What are the optimal conditions for using C3AR1 antibodies in flow cytometry experiments?

For optimal C3AR1 detection by flow cytometry:

• Sample preparation:

  • Use freshly isolated cells when possible

  • For fixed cells, limit paraformaldehyde concentration to 1.6% for 10 minutes at room temperature to preserve epitope integrity

  • Permeabilization (if required): 90% ethanol at -80°C is effective for intracellular epitopes

• Antibody concentration:

  • Titrate antibody to determine optimal concentration (typically 1-10 μg/ml)

  • Include appropriate isotype controls at matching concentrations

• Staining protocol:

  • Add antibody cocktails containing anti-C3AR1 along with lineage markers (e.g., CD34, CD38 for stem cell studies)

  • Incubate in the dark for 20 minutes at 4°C

  • Wash twice with PBS containing 2% fetal bovine serum

  • Add viability dye (e.g., 7AAD or DRAQ7) just before analysis

• Analysis considerations:

  • Gate on viable cells first

  • Compare to isotype controls and known negative populations

  • For dual detection protocols, combine C3AR1 with markers like GPR56 to distinguish leukemic stem cells from normal hematopoietic stem cells

How should I design C3AR1 stimulation experiments to study downstream signaling pathways?

To effectively study C3AR1 downstream signaling:

• Cell preparation:

  • Culture C3AR1-expressing cells in serum-free medium for 12-24 hours prior to stimulation to reduce baseline activity

  • For primary cells, resuspend in serum-free expansion medium after thawing

• C3a stimulation protocol:

  • Use purified human C3a at concentrations ranging from 10-10,000 ng/ml

  • Include vehicle controls (buffer without C3a)

  • For time course experiments, collect samples at early timepoints (1-5 minutes) for phosphorylation events

  • For functional outcomes, continue culture for up to 3 days

• Readout methods for signaling activation:

  • Phospho-flow cytometry targeting pERK1/2 provides single-cell resolution of activation

  • Cell fixation with 1.6% paraformaldehyde for 10 minutes followed by permeabilization with 90% ethanol at -80°C maintains phospho-epitopes

  • Western blot analysis of phosphorylated PTEN and downstream AKT pathway components

• Functional assays following stimulation:

  • Measure cell viability or proliferation using counting beads and viability dyes

  • Assess neutrophil mobilization in response to stimulation

  • Analyze changes in gene expression of known C3aR1 downstream targets

What controls should I include when performing antibody-dependent cellular cytotoxicity (ADCC) assays with anti-C3AR1 antibodies?

For rigorous ADCC assays with anti-C3AR1 antibodies:

• Essential controls:

  • Isotype control antibody: Match the isotype, species, and concentration of the anti-C3AR1 antibody

  • C3AR1-negative cell line: Use as a negative control (e.g., NALM-6)

  • C3AR1-positive cell line: Include as a positive control (e.g., OCI-AML3 for NPM1-mutated AML studies)

  • Effector cell-only control: Include NK cells without target cells or antibody

  • Target cell-only control: Include target cells without NK cells or antibody

• Experimental setup:

  • Label target cells with PKH26 or other fluorescent dye for tracking

  • Test multiple effector-to-target ratios (e.g., 1:1, 5:1, 10:1)

  • Include a dose-response of antibody concentrations

  • Incubate for 4 hours at 37°C, 5% CO₂

• Readout methods:

  • Flow cytometry with viability dyes to assess target cell death

  • Measure cytokine release from NK cells (e.g., IFN-γ, TNF-α)

  • Calculate percent specific lysis relative to spontaneous and maximum lysis controls

• Data presentation:

  • Plot percent specific lysis against antibody concentration

  • Compare results between C3AR1-positive and C3AR1-negative target cells

  • Include statistical analysis comparing anti-C3AR1 antibody to isotype control

How is C3AR1 expression altered in acute myeloid leukemia (AML) and what are the implications for antibody-based therapies?

C3AR1 shows distinctive expression patterns in AML with significant therapeutic implications:

• Expression profile in AML:

  • Selectively upregulated on NPM1-mutated AML cells compared to NPM1 wild-type cases

  • Expression is significantly higher on leukemic cells compared to normal hematopoietic stem cells (HSCs)

  • C3AR1 in combination with GPR56 can distinguish leukemic stem cells from normal HSCs

• Functional significance:

  • C3a/C3AR1 signaling activates ERK1/2 in NPM1-mutated AML cells

  • Activation of this pathway increases survival of AML cells

  • Represents an active signaling axis specific to this AML subtype

• Therapeutic targeting potential:

  • Anti-C3AR1 antibodies efficiently elicit NK cell-mediated killing of primary AML cells ex vivo

  • Antibody-dependent cellular cytotoxicity (ADCC) mechanism shows specificity for NPM1-mutated AML cells

  • Potential for relative sparing of normal HSCs due to their lack of detectable C3AR1 expression

• Clinical implications:

  • C3AR1-targeting may be particularly relevant for the ~30% of AML cases with NPM1 mutations

  • May address treatment needs for patients with relapsed disease despite favorable initial risk stratification

  • Preclinical evidence supports C3AR1 as a candidate therapeutic target in NPM1-mutated AML

What role does C3AR1 play in neutrophil mobilization during inflammation, and how can antibody-based approaches help study this process?

C3AR1 serves as a critical regulator of neutrophil responses during inflammation:

• Regulatory mechanism:

  • C3AR1 engages phosphatase and tensin homolog (PTEN), a negative regulator of the PI3K/AKT pathway

  • This interaction restrains C-X-C chemokine receptor type 2–driven bone marrow neutrophil mobilization

  • Acts as a brake on neutrophil egress following tissue injury

• Physiological consequences:

  • C3AR1 knockout mice (C3ar1-/-) show increased neutrophil infiltration at injury sites

  • Loss of C3AR1 leads to acute granulocytosis in response to trauma

  • Greater neutrophil presence is associated with worsened outcomes in spinal cord injury models

• Antibody-based study approaches:

  • Use anti-C3AR1 antibodies for flow cytometric quantification of receptor expression on neutrophil subsets

  • Employ blocking antibodies to mimic C3ar1-/- phenotype in wild-type models

  • Combine with neutrophil tracking dyes to monitor mobilization and infiltration patterns

  • Use fluorescently-labeled anti-C3AR1 antibodies for intravital microscopy of neutrophil dynamics

• Translational significance:

  • Lower circulating neutrophil numbers at presentation correlate with improved recovery in human spinal cord injury

  • C3AR1 and downstream PTEN pathway represent potential therapeutic targets to inhibit neutrophil mobilization

  • Modulating this pathway could reduce inflammatory pathology following tissue injury

How can I distinguish between active and inactive forms of C3AR1 using specific antibodies?

Differentiating active from inactive C3AR1 requires sophisticated approaches:

• Conformational-specific antibodies:

  • Certain antibodies recognize epitopes exposed only in active receptor conformations

  • Validate conformational specificity by comparing binding before and after C3a stimulation

  • Use live-cell staining at 4°C to capture receptors in native conformations

• Phosphorylation-state specific detection:

  • Following C3a binding, C3AR1 undergoes phosphorylation at specific residues

  • Use phospho-specific antibodies in combination with general C3AR1 antibodies

  • Implement phospho-flow cytometry protocols with brief 1-5 minute C3a stimulation

• Receptor internalization analysis:

  • Active C3AR1 undergoes internalization following ligand binding

  • Use surface vs. intracellular staining protocols to quantify receptor trafficking

  • Employ pH-sensitive fluorescent antibody conjugates to track endosomal localization

• Functional activity correlations:

  • Measure downstream signaling events (ERK1/2 phosphorylation) simultaneously with receptor detection

  • Correlate receptor conformational states with calcium flux measurements

  • Use FRET-based approaches with labeled antibody pairs to detect conformational changes

What strategies can resolve cross-reactivity issues when using C3AR1 antibodies in multi-parameter flow cytometry?

Addressing cross-reactivity in complex flow cytometry panels:

• Panel design considerations:

  • Prioritize antibody clone selection based on validated multi-parameter panels

  • Select fluorophores with minimal spectral overlap for C3AR1 and potentially cross-reactive markers

  • Consider brightness hierarchy: assign brightest fluorochromes to low-expression targets

• Blocking strategies:

  • Implement Fc receptor blocking before adding primary antibodies

  • Use species-matched serum (2-10%) in staining buffer

  • For tissue samples, include avidin/biotin blocking for endogenous biotin

• Validation experiments:

  • Test antibodies individually before combining in full panel

  • Include fluorescence-minus-one (FMO) controls for C3AR1 channel

  • Validate with C3AR1-knockout or siRNA-silenced samples as true negative controls

• Compensation and analysis refinements:

  • Prepare single-color compensation controls with the same cells/beads used in the experiment

  • Implement spectral unmixing algorithms for highly complex panels

  • Use biaxial plots of C3AR1 versus potentially cross-reactive markers to identify true positive populations

  • Compare staining patterns with multiple anti-C3AR1 clones targeting different epitopes

How can I develop a quantitative assay to measure C3AR1 occupancy by therapeutic antibodies in clinical samples?

Developing C3AR1 occupancy assays for clinical applications:

• Competitive binding approach:

  • Use a fluorescently-labeled reporter anti-C3AR1 antibody targeting an epitope distinct from the therapeutic antibody

  • Measure decreased reporter binding as indicator of therapeutic antibody occupancy

  • Establish standard curves with known concentrations of therapeutic antibody

• Direct detection method:

  • Use secondary antibodies specific to the therapeutic antibody's framework

  • Implement a sandwich approach with capture antibodies against C3AR1 and detection antibodies against the therapeutic

  • Develop wash-resistant labeling techniques for stable detection

• Functional occupancy measurement:

  • Measure inhibition of C3a-induced signaling (e.g., ERK1/2 phosphorylation)

  • Compare ex vivo C3a-induced calcium flux in pre- versus post-treatment samples

  • Correlate occupancy with downstream functional markers like neutrophil activation status

• Clinical sample handling:

  • Standardize time between collection and processing (<4 hours)

  • Use stabilization buffers to preserve receptor-antibody complexes

  • Include paired measurements of free therapeutic antibody in plasma

  • Develop cryopreservation protocols that maintain occupancy information

What are the optimal protocols for detecting C3AR1 in different tissue types using immunohistochemistry?

Optimized protocols for C3AR1 immunohistochemistry across tissue types:

• Central nervous system tissues:

  • Fixation: 4% PFA for 24 hours followed by cryoprotection

  • Antigen retrieval: Citrate buffer (pH 6.0) at 95°C for 20 minutes

  • Background reduction: Include 0.3% H₂O₂ treatment and mouse-on-mouse blocking for mouse tissues

  • Detection systems: Tyramide signal amplification recommended for low expression areas

• Immune/hematopoietic tissues:

  • Fixation: Fresh frozen sections or light fixation (1-2% PFA) recommended

  • Sectioning: 5-7 μm thickness optimal for cellular resolution

  • Double staining: Combine with lineage markers (CD34, CD38) for stem cell identification

  • Controls: Include C3ar1-/- tissues or known C3AR1-negative cell populations

• Solid tissue samples:

  • Fixation: Limit to 24 hours in formalin to preserve epitope

  • Blocking: Include avidin-biotin blocking due to endogenous biotin in tissues like liver

  • Cell type identification: Implement dual staining with cell-type markers (GFAP for astrocytes, Iba1 for microglia/macrophages)

  • Quantification: Use digital image analysis with nuclear counterstaining

• General optimization strategies:

  • Compare multiple anti-C3AR1 antibody clones for each tissue type

  • Titrate primary antibody (typical range: 1-10 μg/ml)

  • Evaluate different detection systems (HRP/DAB vs. alkaline phosphatase)

  • Include positive controls with known C3AR1 expression patterns

How should I design and analyze C3AR1 knockout validation experiments for antibody specificity testing?

Comprehensive C3AR1 knockout validation strategy:

• Genetic knockout approaches:

  • CRISPR/Cas9 targeting of early exons to ensure complete protein disruption

  • Conditional knockout systems for tissue-specific validation

  • Verify knockout efficiency at DNA, RNA and protein levels before antibody testing

  • Include heterozygous samples to test antibody sensitivity to expression levels

• Validation experiment design:

  • Test antibodies across multiple applications (WB, flow cytometry, IHC, IF)

  • Include wild-type, heterozygous, and homozygous knockout samples

  • Test in both cell lines and primary cells where possible

  • For chimeric models, evaluate bone marrow transplant efficiency before antibody validation

• Data analysis approach:

  • Quantify signal-to-background ratio in wild-type versus knockout samples

  • Analyze antibody performance across different protein expression levels

  • Implement titration studies to determine optimal antibody concentration

  • Document any non-specific binding patterns observed in knockout tissues

• Addressing potential confounders:

  • Rule out genetic compensation mechanisms in knockout models

  • Verify absence of truncated protein fragments that might retain epitopes

  • Implement siRNA knockdown as complementary approach to genetic knockout

  • Check for potential cross-reactivity with closely related family members

What advanced methods can quantify the affinity and specificity of anti-C3AR1 antibodies for therapeutic development?

Advanced quantitative methods for antibody characterization:

• Surface plasmon resonance (SPR):

  • Determine kon, koff, and KD values for antibody-C3AR1 interactions

  • Compare binding to recombinant extracellular domains versus whole cells

  • Measure competition with natural ligand (C3a) to assess functional binding

  • Evaluate binding kinetics across physiological temperature range

• Bio-layer interferometry (BLI):

  • Real-time measurement of antibody-antigen interactions

  • Determine binding parameters to both human and relevant animal C3AR1 orthologs

  • Assess epitope binning by competitive binding experiments

  • Evaluate stability of antibody-antigen complex under various pH conditions

• Cell-based binding assays:

  • Implement flow cytometry-based Scatchard analysis with calibrated beads

  • Develop competitive binding assays with labeled C3a to assess functional interference

  • Measure antibody internalization rates following binding

  • Compare binding to primary cells versus engineered cell lines

• Functional specificity assessment:

  • Evaluate antagonistic activity in C3a-induced signaling assays (pERK1/2)

  • Measure ADCC potency against cells with varying C3AR1 expression levels

  • Cross-reactivity screening against related GPCRs

  • Species cross-reactivity analysis for translational development

How does C3AR1 expression and function differ between normal immune cells and in pathological conditions?

Comprehensive comparison of C3AR1 in normal versus pathological states:

In pathological conditions, C3AR1 signaling demonstrates contextual functionality:

• In AML: Acts as a pro-survival receptor through ERK1/2 activation

• In CNS trauma: Negatively regulates neutrophil infiltration via PTEN engagement

• In inflammatory disorders: Contributes to neutrophil extravasation and tissue damage

These disease-specific functions make C3AR1 an attractive therapeutic target with context-dependent strategies required for different pathologies.

What methodological approaches can distinguish the roles of C3AR1 in different cell populations within complex tissues?

Advanced methods for cell-specific C3AR1 function analysis:

• Single-cell technologies:

  • Combine flow cytometry with cell sorting to isolate specific C3AR1⁺ populations

  • Implement single-cell RNA sequencing to correlate C3AR1 expression with transcriptional profiles

  • Use CyTOF (mass cytometry) for high-parameter analysis of C3AR1⁺ cells in heterogeneous samples

• Genetic approaches for cell-specific manipulation:

  • Generate conditional C3AR1 knockout models using cell-type specific Cre drivers

  • Implement bone marrow chimeras to distinguish central versus peripheral C3AR1 functions

  • Use cell-specific promoters to drive C3AR1 expression in knockout backgrounds

• Ex vivo functional assays:

  • Isolate specific cell populations for C3a stimulation experiments

  • Compare phospho-flow cytometry responses across different C3AR1⁺ cell types

  • Develop co-culture systems to assess cell-cell interactions mediated by C3AR1

• In vivo imaging approaches:

  • Use fluorescently-labeled anti-C3AR1 antibodies for intravital microscopy

  • Implement reporter mice expressing fluorescent proteins under C3AR1 promoter control

  • Combine with lineage-specific markers for multiplex imaging of C3AR1 function

These methodologies collectively enable researchers to decipher the complex and sometimes opposing roles of C3AR1 in different cell types within the same physiological or pathological context.

How can therapeutic targeting of C3AR1 be optimized to maximize efficacy while minimizing off-target effects?

Strategic approaches for optimized C3AR1-targeted therapeutics:

• Epitope selection considerations:

  • Target epitopes unique to C3AR1 that are minimally conserved in related GPCRs

  • Select functional epitopes that directly interfere with C3a binding or receptor activation

  • Consider accessibility in disease-relevant tissues and cell types

• Antibody format optimization:

  • Compare conventional IgG formats with fragment-based approaches (Fab, scFv)

  • Evaluate bispecific antibodies targeting C3AR1 and disease-relevant cell markers

  • Consider pH-dependent binding antibodies for improved tissue penetration

• Therapeutic mechanisms:

  • For inflammatory conditions: Blocking antibodies to inhibit C3a-mediated activation

  • For NPM1-mutated AML: ADCC-optimized antibodies for targeted cell killing

  • For neutrophil-driven pathologies: Antibodies targeting C3AR1-PTEN interaction

• Precision medicine approaches:

  • Develop companion diagnostics to identify patients with C3AR1-dependent disease

  • Implement C3AR1 expression profiling to predict therapeutic response

  • Design treatment protocols based on disease-specific C3AR1 biology